Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Phase of Trial: Phase II
Latest Information Update: 18 May 2015
At a glance
- Drugs Everolimus (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 25 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Sep 2011 Planned end date changed from Dec 2011 to Dec 2012 as reported by ClinicalTrials.gov.